June 18, 2008 - Elekta received FDA 510(k) clearance for its volumetric intensity modulated arc therapy (VMAT) solution that reportedly combines a significant reduction in treatment time with optimal avoidance of radiation dose to healthy tissues surrounding the tumor.
According to Elekta, the reduction in treatment time makes it easier to accurately target the tumor and the improved dose sparing offers new options to either increase dose to tumor or reduce side effects and therefore potentially improve outcomes. For the clinic administrator, reduced treatment times and the opportunity to increase dose and reduce the number of treatment sessions increases the number of patients that can be treated using their existing equipment.
Elekta is uniquely positioned to introduce the VMAT technique by virtue of Elekta Synergy, what is said to be the only fully digital linear accelerator with integrated high-resolution 3D X-ray Volume Imaging (XVI). With daily pre-treatment imaging scans, clinicians who implement Elekta VMAT will be able to maximize accuracy and shrink treatment margins, while minimizing the possibility of damage to surrounding healthy tissue.
For more information: www.elekta.com
March 28, 2024 
